Objective: To describe chemotherapy treatments, associated health care use and costs, and survival for women diagnosed with cervical cancer in the United States. Methods: This was a retrospective cohort study of patients aged ≥65 years, identified in linked Surveillance, Epidemiology, and End Results (SEER) and Medicare databases. Women with a new primary diagnosis of cervical cancer between January 2007 and December 2013 were followed until December 2014. Systemic chemotherapy treatments, health care visits and costs (2016 USD rates), and survival were determined by the line of therapy. Results: Of 1651 women in the analysis, 810 (49.1%) were diagnosed at stages I or II, 411 (24.9%) at stage III, and 430 (26.0%) at stage IV. A total of 225 (13.6%) women received first-line (1L) systemic chemotherapy. Of those who received 1L chemotherapy, 73 (32.4%) received second-line (2L) chemotherapy, and 29 (12.9%) received third-line (3L) chemotherapy. During 1L and 2L chemotherapies, patients averaged 5.9 and 6.5 health care visits per month, respectively, and incurred total mean health care costs per patient per month of $7098 and $8770, respectively. Median survival from the start of 1L and 2L chemotherapy was 14.0 and 10.4 months, respectively. Conclusion: Elderly patients with advanced cervical cancer had a poor prognosis, with a median survival of 14 months or less, and had no standard of care for 2L therapy. Systemic chemotherapies pose a substantial economic burden in the range of $7000 to $9000 per patient per month. These results highlight the high unmet medical need among elderly patients with cervical cancer.
Objective: To describe chemotherapy treatments, associated health care use and costs, and survival for women diagnosed with cervical cancer in the United States. Methods: This was a retrospective cohort study of patients aged ≥65 years, identified in linked Surveillance, Epidemiology, and End Results (SEER) and Medicare databases. Women with a new primary diagnosis of cervical cancer between January 2007 and December 2013 were followed until December 2014. Systemic chemotherapy treatments, health care visits and costs (2016 USD rates), and survival were determined by the line of therapy. Results: Of 1651 women in the analysis, 810 (49.1%) were diagnosed at stages I or II, 411 (24.9%) at stage III, and 430 (26.0%) at stage IV. A total of 225 (13.6%) women received first-line (1L) systemic chemotherapy. Of those who received 1L chemotherapy, 73 (32.4%) received second-line (2L) chemotherapy, and 29 (12.9%) received third-line (3L) chemotherapy. During 1L and 2L chemotherapies, patients averaged 5.9 and 6.5 health care visits per month, respectively, and incurred total mean health care costs per patient per month of $7098 and $8770, respectively. Median survival from the start of 1L and 2L chemotherapy was 14.0 and 10.4 months, respectively. Conclusion: Elderly patients with advanced cervical cancer had a poor prognosis, with a median survival of 14 months or less, and had no standard of care for 2L therapy. Systemic chemotherapies pose a substantial economic burden in the range of $7000 to $9000 per patient per month. These results highlight the high unmet medical need among elderly patients with cervical cancer.
Entities:
Keywords:
Drug therapy; SEER program; resources/economics/utilization; treatment outcomes